Rhythm Pharmaeuticals

Business acquisition
#Mergers and acquisitions #Rare disease #Rhythm Pharmaeuticals #Xinvento

Rhythm Pharmaceuticals buys biotech focused on rare disease

Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).  CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death.   Xinvento… Read More

#Business & Investment #News